BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in shares of Zoetis Inc (NYSE:ZTS) by 3.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 465,865 shares of the company’s stock after purchasing an additional 16,836 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Zoetis were worth $33,561,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Zoetis during the fourth quarter valued at approximately $108,000. We Are One Seven LLC acquired a new stake in Zoetis during the fourth quarter valued at approximately $120,000. Premia Global Advisors LLC acquired a new stake in Zoetis during the fourth quarter valued at approximately $122,000. Icon Wealth Partners LLC acquired a new stake in Zoetis during the fourth quarter valued at approximately $127,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in Zoetis during the third quarter valued at approximately $114,000. Hedge funds and other institutional investors own 92.29% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, insider Heidi C. Chen sold 7,383 shares of the stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $84.71, for a total value of $625,413.93. Following the completion of the transaction, the insider now directly owns 20,162 shares of the company’s stock, valued at approximately $1,707,923.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the transaction, the executive vice president now directly owns 49,919 shares of the company’s stock, valued at $4,044,437.38. The disclosure for this sale can be found here. Insiders sold a total of 112,952 shares of company stock valued at $9,219,843 over the last three months. Corporate insiders own 0.31% of the company’s stock.

Several analysts have issued reports on ZTS shares. Morgan Stanley upgraded Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective on the stock in a research note on Wednesday, November 29th. Citigroup upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Thursday, January 4th. UBS reiterated a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Cantor Fitzgerald set a $85.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Thursday, January 11th. Finally, Jefferies Group set a $97.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Monday, February 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $79.72.

Zoetis Inc (NYSE ZTS) opened at $82.06 on Friday. Zoetis Inc has a fifty-two week low of $52.25 and a fifty-two week high of $85.73. The stock has a market capitalization of $41,081.58, a P/E ratio of 46.89, a P/E/G ratio of 1.90 and a beta of 0.97. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.85 and a quick ratio of 2.55.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the company posted $0.47 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. analysts anticipate that Zoetis Inc will post 3.04 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio (DPR) is 28.57%.

COPYRIGHT VIOLATION NOTICE: “BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Increases Holdings in Zoetis Inc (ZTS)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/british-columbia-investment-management-corp-increases-holdings-in-zoetis-inc-zts/1959097.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.